Vilnius-based biotech company Atrandi Biosciences has raised $25 million in a Series A funding round, which was led by Lux Capital, Endpoints News reports. Vsquared Ventures, Practica Capital, Metaplanet, and GRIDS Capital also participated in the financing to help Atrandi expand single-cell research in the UK.
About Atrandi Biosciences
- Founded in 2016 by Linas Mazutis, Atrandi Biosciences develops innovative microfluidic solutions for the life sciences, which the company calls droplet microfluidics technology.
- These solutions enable compartmentalizing molecular biology reactions into millions of pico-liter droplets that can provide researchers around the world with the tools and support to accelerate scientific discovery and innovation, like the study of blood, tumors, pathogens, and engineered cell lines.
“Our work is at the intersection of life sciences, engineering, and machine learning. We deliver elegant solutions and novel tools for groundbreaking high-throughput research by integrating different technologies,” Atrandi states.
- Atrandi's product pipeline includes Flux, a specialized SPC generation device with a user‑friendly, single–button operation, and Onyx, a versatile platform for SPC innovators, allowing flexible parameter adjustment, as well as Styx, a high-throughput screening platform.
Investment details
Lux Capital is the lead investor in this round, which was also joined by Vsquared Ventures, Practica Capital, Metaplanet, and GRIDS Capital.
- Lux Capital is a US-based venture capital firm specializing in early-stage investments in deep tech, life sciences, and frontier technology. Founded in 2000, it backs startups that push the boundaries of science and innovation, from AI and biotech to space and robotics.
- Practica Capital is a Lithuanian venture capital firm focused on early-stage investments in the Baltic region. It primarily backs technology-driven startups, supporting them from seed to growth stages with a hands-on approach.
- Metaplanet is an Estonian venture capital firm investing in deep tech, AI, biotech, and other frontier technologies. Known for its bold, long-term vision, it supports high-impact startups globally, including those in CEE.
The funding will support Atrandi’s expansion into the US market, further development of its microfluidic platforms, and the launch of new products.
This investment follows Atrandi Biosciences' €4.5 million funding raised in March 2023 also for its Series A round.
